Module Description: At the conclusion of this activity participants should be able to describe the historical evolution and current state of the policies regulating office based prescribing of medications for opioid use disorder, and distinguish these from the federal regulations applicable to opioid treatment programs (OTPs). Participants will also be able to which identify which prescribing clinicians are eligible for the DATA-2000 waiver, the applicable waiver limits including the relevant practice settings impacting waiver limits, and the specific medications for opioid use disorder and clinic settings where the DATA-2000 does not apply. Participants will also be able to explain applicable privacy regulations and the regulations governing managing medications for opioid use disorder via telehealth. 

Educational Objectives:

• Describe the legal differences between an opioid treatment program (OTP), hospital-managed MOUD, and office-based opioid treatment
• Identify how X-waivered clinicians can increase their cap to increase the number of patients they can treat concurrently with buprenorphine products
• Understand the rules regulating treating opioid use disorder with buprenorphine or methadone
• Explain confidentiality rules governing substance use treatment records
• Demonstrate how to appropriately manage MOUD using telemedicine